Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.